Cell-bound complement activation products in SLE

Area of Science:

• Immunology
• Rheumatology

Background:

• Systemic Lupus Erythematosus (SLE) diagnosis relies on clinical and laboratory findings but is challenging due to heterogeneous presentation and disease activity fluctuations.
• Autoantibodies are key diagnostic markers, but traditional complement protein measurements (C3, C4) may not accurately reflect complement system activation in SLE patients.

Purpose of the Study:

• To review the role of the complement system, specifically cell-bound complement activation products (CB-CAPs), as biomarkers for SLE diagnosis and monitoring.
• To compare the utility of CB-CAPs with traditional complement proteins and other activation markers for SLE management.

Main Methods:

• Review of existing literature on SLE diagnosis and biomarkers.
• Focus on immunological laboratory tests, including autoantibodies and complement activation products.
• Analysis of cell-bound complement activation products (CB-CAPs) as potential diagnostic and monitoring tools.

Main Results:

• Heterogeneity in SLE symptoms complicates diagnosis.
• Standard autoantibody tests (ANA, anti-dsDNA, anti-Sm) are crucial for SLE classification.
• Cell-bound complement activation products (CB-CAPs) offer a more direct measure of complement activation compared to serum C3 and C4 levels.

Conclusions:

• CB-CAPs represent a promising biomarker for improved SLE diagnosis and monitoring.
• Further research into CB-CAPs could enhance the management of SLE by providing more accurate insights into disease activity and complement system engagement.